379 related articles for article (PubMed ID: 21278072)
1. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
3. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
4. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
6. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
7. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
8. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
9. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
[TBL] [Abstract][Full Text] [Related]
10. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
12. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
13. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
Ezeonyeji AN; Isenberg DA
Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
15. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
Gilani ST; Khan DA; Khan FA; Ahmed M
J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
[TBL] [Abstract][Full Text] [Related]
17. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
18. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
[TBL] [Abstract][Full Text] [Related]
20. Frequency of adverse drug reactions in patients with systemic lupus erythematosus.
Pope J; Jerome D; Fenlon D; Krizova A; Ouimet J
J Rheumatol; 2003 Mar; 30(3):480-4. PubMed ID: 12610805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
